Skip to main content

Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma

Tracking # 20-1288694

Free

There are no ratings for this course

Learn more
Educator I3 HEALTH
CE Broker Reporting Reported automatically
Method Computer-Based Training

Course overview

Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche into circulation. Stem cell mobilization strategies differ in terms of stem cell yields, safety considerations, and resource utilization, and mobilization failure remains a concern in spite of the incorporation of novel agents into conventional methods. Therefore, it is crucial that clinicians apply interdisciplinary strategies to mitigate poor mobilization and optimize ASCT outcomes (Wei & Wei, 2023). In this activity, Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center and Assistant Professor of Clinical Medicine at Weill Cornell Medical College, will share insights into cracking the code to successful stem cell mobilization in multiple myeloma.

Subject areas

This course counts toward the state boards and subject areas below.

Arkansas State Board of Nursing

Certified Nurse Practitioner

0.75h Practice-Focused Continuing Education

Clinical Nurse Specialist

0.75h Practice-Focused Continuing Education

Licensed Practical Nurse

0.75h Practice-Focused Continuing Education

Registered Nurse

0.75h Practice-Focused Continuing Education

Registered Nurse Practitioner

0.75h Practice-Focused Continuing Education

Georgia Board of Nursing

Licensed Practical Nurse

0.75h General

Registered Professional Nurse

0.75h General

Kansas State Board of Nursing

Clinical Nurse Specialist

0.75h Approved CNE Related to the Advanced Practice Registered Nurse

Licensed Practical Nurse

0.75h Continuing Nursing Education (CNE)

Nurse Practitioner

0.75h Approved CNE Related to the Advanced Practice Registered Nurse

Registered Nurse

0.75h Continuing Nursing Education (CNE)

New Hampshire Board of Nursing

Advanced Practice Registered Nurse

0.75h General CE

Licensed Practical Nurse

0.75h General CE

Registered Nurse

0.75h General CE

New Mexico Board of Nursing

Certified Nurse Practitioner

0.75h Continuing education relevant to nursing practice

Certified Registered Nurse Anesthetist

0.75h Continuing education relevant to nursing practice

Clinical Nurse Specialist

0.75h Continuing education relevant to nursing practice

Licensed Practical Nurse

0.75h Continuing education relevant to the licensed practical nurse

Registered Nurse

0.75h Continuing education relevant to nursing practice

North Dakota Board of Nursing

Advanced Practice Registered Nurse

0.75h CE Related to Nursing Practice

Licensed Practical Nurse

0.75h CE Related to Nursing Practice

Registered Nurse

0.75h CE Related to Nursing Practice

South Carolina Board of Nursing

Advanced Practice Registered Nurse

0.75h General

Licensed Practical Nurse

0.75h General

Registered Nurse

0.75h General

Disclosure statements

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Hamza Hashmi, MD, discloses that he has served on an advisory board or panel for Janssen and that he has served on a speaker's bureau for Amgen, Janssen, and Karyopharm. 

i3 Health has mitigated all relevant financial relationships.